These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 35757470)
21. HPIP promotes thyroid cancer cell growth, migration and EMT through activating PI3K/AKT signaling pathway. Wang SC; Chai DS; Chen CB; Wang ZY; Wang L Biomed Pharmacother; 2015 Oct; 75():33-9. PubMed ID: 26463629 [TBL] [Abstract][Full Text] [Related]
22. Oncogenic pseudogene DUXAP10 knockdown suppresses proliferation and invasion and induces apoptosis of papillary thyroid carcinoma cells by inhibition of Akt/mTOR pathway. Li J; Jiang L; Liu Z; Li Y; Xu Y; Liu H Clin Exp Pharmacol Physiol; 2020 Aug; 47(8):1473-1483. PubMed ID: 32215944 [TBL] [Abstract][Full Text] [Related]
23. Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells in Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Signaling Pathway. Li C; Zhou Y; Cai Y; Shui C; Liu W; Wang X; Jiang J; Zeng D; Gui C; Sun R Med Sci Monit; 2019 Jul; 25():5054-5061. PubMed ID: 31322140 [TBL] [Abstract][Full Text] [Related]
24. LPAR5 promotes thyroid carcinoma cell proliferation and migration by activating class IA PI3K catalytic subunit p110β. Zhao WJ; Zhu LL; Yang WQ; Xu SJ; Chen J; Ding XF; Liang Y; Chen G Cancer Sci; 2021 Apr; 112(4):1624-1632. PubMed ID: 33540491 [TBL] [Abstract][Full Text] [Related]
25. MicroRNA-31 inhibits papillary thyroid carcinoma cell biological progression by directly targeting SOX11 and regulating epithelial-to-mesenchymal transition, ERK and Akt signaling pathways. Wang Y; Liu BG; Zhou CX Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5863-5873. PubMed ID: 31298337 [TBL] [Abstract][Full Text] [Related]
26. CDK12 Promotes the Proliferation, Migration, and Angiogenesis of Gastric Carcinoma via Activating the PI3K/AKT/mTOR Signaling Pathway. Gao LZ; Wang JQ; Chen JL; Zhang XL; Zhang MM; Wang SL; Zhao C Appl Biochem Biotechnol; 2023 Nov; 195(11):6913-6926. PubMed ID: 36951936 [TBL] [Abstract][Full Text] [Related]
27. GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT/mTOR and JAK/STAT3 pathways in anaplastic thyroid carcinoma. Gao H; Wang W; Li Q Cancer Biol Ther; 2022 Dec; 23(1):369-377. PubMed ID: 35491899 [TBL] [Abstract][Full Text] [Related]
28. APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K-Akt-mTOR signaling. Liu Y; Liu Q; Chen S; Liu Y; Huang Y; Chen P; Li X; Gao G; Xu K; Fan S; Zeng Z; Xiong W; Tan M; Li G; Zhang W FASEB J; 2019 Nov; 33(11):11959-11972. PubMed ID: 31408612 [TBL] [Abstract][Full Text] [Related]
29. [P4HA2 promotes occurrence and progression of liver cancer by regulating the PI3K/Akt/mTOR signaling pathway]. Shang L; Jiang W; Zhang J; Wu W Nan Fang Yi Ke Da Xue Xue Bao; 2022 May; 42(5):665-672. PubMed ID: 35673909 [TBL] [Abstract][Full Text] [Related]
30. Rhodiolin inhibits the PI3K/AKT/mTOR signaling pathway via the glycolytic enzyme GPI in human papillary thyroid cancer. Bo J; Mao S; Yang J; Wang L; Zheng J; Zhang C; Song M; Chen S; Liu C Phytomedicine; 2024 Sep; 132():155804. PubMed ID: 38943696 [TBL] [Abstract][Full Text] [Related]
31. MicroRNA-26a suppresses the malignant biological behaviors of papillary thyroid carcinoma by targeting ROCK1 and regulating PI3K/AKT signaling pathway. Wu YC; Li SY; Jia YF Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8940-8949. PubMed ID: 31696481 [TBL] [Abstract][Full Text] [Related]
32. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways. Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111 [TBL] [Abstract][Full Text] [Related]
33. STEAP2 promotes osteosarcoma progression by inducing epithelial-mesenchymal transition via the PI3K/AKT/mTOR signaling pathway and is regulated by EFEMP2. Zhang D; Liu H; Wang W; Xu G; Yin C; Wang S Cancer Biol Ther; 2022 Dec; 23(1):1-16. PubMed ID: 36316642 [TBL] [Abstract][Full Text] [Related]
34. MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway. Zhao J; Li Z; Chen Y; Zhang S; Guo L; Gao B; Jiang Y; Tian W; Hao S; Zhang X Int J Oncol; 2019 Jan; 54(1):315-325. PubMed ID: 30387841 [TBL] [Abstract][Full Text] [Related]
35. Silencing of Long Non-coding RNA ENST00000606790.1 Inhibits the Malignant Behaviors of Papillary Thyroid Carcinoma through the PI3K/AKT Pathway. Zuo Z; Liu L; Song B; Tan J; Ding D; Lu Y Endocr Res; 2021 Feb; 46(1):1-9. PubMed ID: 32791924 [TBL] [Abstract][Full Text] [Related]
36. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway. Zeng L; Liao Q; Zou Z; Wen Y; Wang J; Liu C; He Q; Weng N; Zeng J; Tang H; Fang R; Lei Z; Tang Z; Yang X; Cui S Cell Physiol Biochem; 2018; 51(3):1221-1236. PubMed ID: 30481766 [TBL] [Abstract][Full Text] [Related]
37. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis. Cui Z; Luo Z; Lin Z; Shi L; Hong Y; Yan C J Gene Med; 2019 May; 21(5):e3083. PubMed ID: 30811764 [TBL] [Abstract][Full Text] [Related]
38. Mechanism of RET gene mediated EGFR signaling pathway on epithelial-mesenchymal transition, proliferation and apoptosis of papillary thyroid carcinoma cells. Zhao YL; Yuan BQ; Shen GS Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):8036-8047. PubMed ID: 32767330 [TBL] [Abstract][Full Text] [Related]
39. N-cadherin promotes thyroid tumorigenesis through modulating major signaling pathways. Da C; Wu K; Yue C; Bai P; Wang R; Wang G; Zhao M; Lv Y; Hou P Oncotarget; 2017 Jan; 8(5):8131-8142. PubMed ID: 28042956 [TBL] [Abstract][Full Text] [Related]
40. M2‑like tumour‑associated macrophage‑secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K/AKT/mTOR pathway. Lv J; Liu C; Chen FK; Feng ZP; Jia L; Liu PJ; Yang ZX; Hou F; Deng ZY Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34184083 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]